Prenetics Global Limited (PRE) AI Stock Analysis

Prenetics Global Limited, an investment holding company based in Quarry Bay, Hong Kong, operates in diagnostics and genetic testing. Founded in 2014, the company offers a range of health testing solutions. Flagship products include CircleDNA, a consumer genetic testing product providing personalized genetic insights, and Circle HealthPod, a health monitoring system enabling rapid detection through nucleic acid amplification tests for point-of-care or at-home COVID-19 screening. The company also offers ColoClear, a non-invasive FIT-DNA colorectal cancer screening test, and Circle SnapShot, an off-the-shelf at-home blood test, serving individuals seeking comprehensive health diagnostics.

Revenue expanded from $12.5M in FY2021 to $92.4M in FY2025, reflecting a 5-year revenue CAGR of 7.2%. Annual growth accelerated to 201.7% in FY2025, following 40.8% growth in FY2024 and 65.2% in FY2023. Gross margin widened from 28.7% in FY2021 to 52.8% in FY2025. Despite top-line gains, the company remains unprofitable. Operating margin stood at -41.3% in FY2025, improving from -157.2% in FY2024, with net income of -$37.7M and EPS of -$2.54. For the latest quarter ended June 30, 2026, quarterly revenue grew 210.7% year-over-year, while trailing twelve-month revenue reached $154.6M with an operating margin of -45.1%.

As of June 30, 2026, Prenetics held $109.4M in cash and short-term investments against $682,000 in total debt, resulting in a net cash position of $108.7M. Total assets stood at $153.7M against shareholders' equity of $93.0M. The company maintains liquidity with a current ratio of 4.04 and a debt-to-equity ratio of 0.01. Operating cash flow in FY2025 was -$21.8M and free cash flow was -$22.0M, with capital expenditures of $208,000. Its share count increased 366.8% over five years.

At a last close of $18.52, Prenetics has a market capitalization of $361.4M and an enterprise value of $171.2M. The stock trades at a price-to-sales multiple of 2.3x and an EV/EBITDA of 0.1x, compared to the median of its US-listed Consumer Defensive peers of 0.7x price-to-sales and 11.7x EV/EBITDA. Its price-to-book ratio is 1.3x. Over the past year, the stock returned 16.8%, matching the S&P 500 return of 16.8%, while over five years it fell 83.9% compared to an 83.0% gain for the benchmark index.

Wall Street coverage includes 6 Strong Buy ratings, with no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $38.12, representing upside of 105.9% from the last close of $18.52. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $224.2M and EPS of -$3.54. For the following fiscal year, 4 analysts estimate revenue of $404.5M, reflecting 80.4% revenue growth, and EPS of -$2.39. Prenetics has beaten EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Prenetics Global Limited (PRE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PRE income statement, PRE balance sheet, PRE key metrics, PRE analyst forecast, PRE chart. See the PRE stock overview for the latest quote and news.